SHGB

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Retrieved on: 
Wednesday, December 13, 2023
Liver, Marketing, Hypogonadism, Risk, PRIME, FDA, TRT, WCS, Telehealth, Absorption, Fatigue, Health, Softgel, Site, SHGB, Conditional sentence, Obesity, Lymphatic system, DTC, Patient, Endocrine system, Erectile dysfunction, Pharmaceutical industry

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Key Points: 
  • KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts.
  • PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel.
  • KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels.